Intra-articular administration of MD-Hip in 24 patients affected by symptomatic hip osteoarthritis – A 24-month cohort study

Intra-articular administration of MD-Hip in 24 patients affected by symptomatic hip osteoarthritis – A 24-month cohort study

 

30/07/2021 10:55 GMT+7

Dr. Francesca Giovannangeli, MD

UOS of Rheumatology, S. Pietro Fatebenfratelli Hospital, Via Cassia, 600 00189 Rome, Italy

SUMMARY

The aim of this clinical trial is to report the efficacy and safety profiles of MD-Hip in patients affected by hip OA.

24 patients (10 M; 14 F) were enrolled in the study; none of them suffered from bilateral hip OA.

All parameters improved after the first injection, and improvement kept increasing during the whole 24-month follow-up.
No infectious complications were reported; 1 patient reported a transient discomfort in the treated hip for 1 day after the injection, which regressed spontaneously.

Our data suggest that the beneficial effects obtained by the ultrasound-guided intra-articular injection of the hip joint are present after the very first injection and are maintained over 24 months by the repetition of intra-articular injection every 6 months.

KEY WORDS

Hip, osteoarthritis, MD-Hip.

BACKGROUND

Previous clinical data on cohorts of patients undergoing intra-articular injections with hyaluronic acids or hylans, under ultrasonographic guidance with a 3-48 month follow-up showed good safety and efficacy, with results similar to those already obtained in other studies on knee joint viscosupplementation.

Ultrasound guidance allows a better rate of success in the hip intra-articular injections.
No data are currently available in the scientific literature reporting safety and efficacy profiles of MD-Hip in patients affected by hip osteoarthritis undergoing ultrasound-guided intra-articular injections of the hip.

AIM OF THE STUDY

The aim of this study is to report the efficacy and safety profiles of MD-Hip in patients affected by hip OA.

MATERIALS AND METHODS

Adult patients suffering from hip OA grade 1-3 according to Kellgren and Lawrence scale were considered eligible for the study.

Patients were injected with one syringe (2 vials) of Guna Collagen MD-Hip under ultrasound guidance.
A 3.5 MHz convex transducer was used with a sterilized biopsy guide attached. The hip joint was scanned through an anterior parasagittal approach.

The efficacy was assessed by using the Lequesne Index and VAS pain score at baseline and then every 6 months after the first injection of MD-Hip.

NSAIDs consumption was also evaluated during the month before the injection (number of days of NSAIDs use in the last month) and then every 6 months after the first injection of MD-Hip until month 24.

– Safety was assessed by recording any adverse event during the follow-up.

RESULTS

24 patients (10 M; 14 F) were enrolled in the study; none of them suffered from bilateral hip OA.
– All parameters improved after the first injection, and improvement kept increasing during the whole 24-month follow-up. No infectious complications were reported; 1 patient reported a transient discomfort in the treated hip for 1 day after the injection, which regressed spontaneously.

CONCLUSIONS

Our data suggest that the beneficial effects obtained by the ultrasound-guided intra-articular injection of the hip joint are present after the very first injection and are maintained over 24 months by the repetition of intra-articular injection every 6 months (FIGURE 1).

– Guna Collagen MD-Hip proved to be efficacious and safe when used in patients affected by hip OA.
This introduces new investigation aims in the field of intra-articular therapy.

Citation

F. Giovannangeli, E. Bizzi, U. Massafra, F. Vacca, S. Tormenta, A. Migliore (2017), “Intra-articular administration of MD-Hip in 24 patients affected by symptomatic hip osteoarthritis – A 24-month cohort study”, Physiological regulating medicine 2016 – 2017, 31-32.